Epirubicin
GI Cancer
M.D. Anderson Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the GI Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mlf 541 B. Braun Melsungen AG | Phase 3 | BB |
cgx1321 Curegenix Inc. | Phase 1 | CC |
Pembrolizumab M.D. Anderson Cancer Center | Phase 1 | CC |
Encorafenib Curegenix Inc. | Phase 1 | CC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →